Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Futura Medical confirms Europe launch of MED3000; awaits FDA approval

14th Mar 2023 14:33

(Alliance News) - Futura Medical PLC on Tuesday said its MED3000 product is now available online in Europe under the brand name Erexon.

The sexual health-focused pharmaceutical company, based in Surrey, England, said Erexon will also be available to buy in pharmacies in Belgium as of April.

This comes after Futura Medical announced a licensing agreement with Cooper Consumer Health last year for the rights to commercialise MED3000 in Europe, Switzerland and the UK.

MED3000 is a gel developed by Futura Medical used to treat erectile dysfunction.

The company also said it applied for US marketing authorisation for MED3000, which is undergoing a review. The US Food and Drug Administration has asked questions on MED3000, which Futura Medical plans to respond to at the end of the month.

Chief Executive Officer James Barder said the company expects to be granted market authorisation by the FDA in the second half of 2023.

If successful, MED3000 would become the first globally available, clinically proven, over the counter treatment for erectile dysfunction.

Shares were down 3.8% at 48.19 pence in London on Tuesday afternoon.

By Sabrina Penty; Alliance News reporter

Comments and questions to [email protected]

Copyright 2023 Alliance News Ltd. All Rights Reserved.


Related Shares:

Futura Medical
FTSE 100 Latest
Value8,275.66
Change0.00